Leveraging Data Intelligence for Effective Opportunity Screening and Prioritization in Drug Discovery

Case Study

Challenge

Our biotech client needed an innovative, effective way to identify which binding sites and therapeutic indications they should target for the development of new therapeutic agents for oncological applications.  

However, the traditional approach to periodically screening and prioritization requires significant effort and resources to: 

  • Develop predictive models for target prioritization that aligns with the global strategy of the company and considers the potential clinical and commercial value 
  • Continually monitor the latest advancements in scientific production to systematically review new opportunities over the time 

Scouting and evaluating targets in this way demands considerable resources and requires recurrent efforts for each review. Additionally, failing in even one of these activities undermines the capacity of the R&D team to timely identify suitable opportunities and reduce the time to market to leverage those opportunities. 

Our Solution

Our data analytics and technology experts have developed a customizable, actionable digital solution that support strategic decision-making. Utilizing our business strategists, scientists, and software developers, this tailored solution outlines the best fit for the company’s strategic priorities and capabilities.  

To deliver comprehensive analytics that our client could immediately action on, we followed a multi-step process: 

Step 1: Integrated biological evidence and drug data sources  

  • Identified over 5,000 biological targets and more than 1,000 clinical indications in the company’s top therapeutic areas 
  • Integrated drug and scientific evidence on biological target and indication from seven databases 
  • Cross-referenced information to create a knowledge base of more than 130,000 biological target-indication associations and 12,000 drugs 

Step 2: Developed a prioritization model based on scientific and market evaluations 

  • Defined parameters that condensed the information into a few relevant metrics 
  • Developed scoring criteria and ranking rules for biological target-indication associations  
  • Defined default algorithm weights according to scientific relevance and underlying business potential of each criterium 

Step 3: Provided expert support and indication prioritization   

  • Developed an intuitive, web-based tool that allowed users to explore data, tune model weights, and achieve different prioritization outcomes depending on assumptions 
  • Delivered training sessions to help identify the final prioritized list of associations 
  • Leveraged AI-assisted data mining to prioritize associations through the analysis of clinical, commercial, and health economics endpoints  

Outcome 

The complete, customized solution allows our client to explore the full spectrum of R&D opportunities through the integration of multiple public and private data sources and an actionable prioritization algorithm. With our deep industry knowledge and therapeutic expertise, we can leverage the power of data to develop tailored digital solutions that reduce the burden of data mining and early opportunity assessment. The client can also rely on these additional benefits of our analytics: 

  • Reduction of human-error related risks in data analysis   
  • Reduction of time and financial effort required by manual data gathering and analysis 
  • Enhanced interdepartmental collaboration  
  • Optimized opportunity review process that utilizes continually updated data 

Ready to fuel your decision-making by unlocking the power of data?

Related news

News January 25, 2023
Myasthenia Gravis Foundation of America (MGFA) Re-launches the MGFA Global MG Patient Registry with Partner Alira Health
The registry enables patients diagnosed with MG to securely, safely submit their health and symptom data that will help researchers design and drive new research studies and clinical(...)
Clinical Trials Digital Health Patient Advocacy
News January 23, 2023
TerSera Therapeutics to sponsor “NET Cancer Health Storylines” by Alira Health and Carcinoid Cancer Foundation to support patients suffering from Carcinoid Syndrome Diarrhea
We are pleased to announce TerSera Therapeutics’ sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to expand and optimize a holistic patient journey digital(...)
Digital Health Digital Therapeutics Patient Centricity
Publications January 20, 2023
Insights on Market Access
To get her perspective on market access and what to expect in 2023, we spoke with Nerea Blanqué, Senior Vice President of Market Access and Pricing at Alira Health.
Market Access Medical Devices Pharma
Publications January 18, 2023
The State of Biopharma Funding
We spoke with Joris Pezzini, Executive Vice President of Biopharma, Alira Health, during the J.P. Morgan Healthcare Conference in San Francisco, which brings together investors and(...)
Biopharma Biotech Funding Pharma
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
News November 15, 2022
Alira Health Partners with Policy Matters to Foster Market Access in the UK
Alira Health, a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, announces its partnership with leading UK market access specialist(...)
Digital Health Healthcare Consulting Market Access
News November 10, 2022
Alira Health and GDMH together to boost Life Sciences innovation
The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.
Clinical Trials Digital Health DTx Market Access Real-World Evidence RWE
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.